Gene Expression Profiling in Type 1 Diabetes
1 other identifier
observational
64
1 country
1
Brief Summary
One of the goals of the Kansas City Diabetes Consortium is to identify and characterize genes and their products that are associated with T1DM. Characterization of such genes and their products can aid in developing new tools for risk assessment, development of new prevention strategies and monitoring progression of disease. Study design: Descriptive, basic science pilot study. The results of this pilot study will be used to help design a much larger study to address the importance of viral response and autoimmune diabetes.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Jun 2006
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 26, 2006
CompletedFirst Posted
Study publicly available on registry
May 29, 2006
CompletedStudy Start
First participant enrolled
June 1, 2006
CompletedStudy Completion
Last participant's last visit for all outcomes
April 1, 2008
CompletedMarch 5, 2010
March 1, 2010
May 26, 2006
March 3, 2010
Conditions
Keywords
Eligibility Criteria
Male and female subjects 7-14 years of age * New onset T1DM * Five years post onset of T1DM
You may qualify if:
- Male and female subjects 7-14 years of age
- New onset T1DM
- Five years post onset of T1DM
- Participant in the TrialNet initiative and either antibody positive or antibody negative sibling control
- Body weight sufficient to tolerate an additional 15ml (1 tbsp) blood loss
You may not qualify if:
- Subjects who do not meet the criteria above
- Subjects who have received steroids or other immunosuppressive therapy within the 6 months prior to enrollment into the study
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Children's Mercy Hospital
Kansas City, Missouri, 64108, United States
Biospecimen
Whole Blood saved frozen for 1 year
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Karen Kover, PhD
Children's Mercy Hospital Kansas City
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
May 26, 2006
First Posted
May 29, 2006
Study Start
June 1, 2006
Study Completion
April 1, 2008
Last Updated
March 5, 2010
Record last verified: 2010-03